Research applications in the areas of breast, kidney, lung, pancreatic, prostate, ovarian, rare cancer, or melanoma are prohibited by congressional language and will be rejected. The inclusion of the individual Rare Cancers Research Program shall not prohibit the funding of the FY23 PRCRP congressionally directed cancers or cancer subtypes that may be rare by definition.

• Bladder cancer
• Blood cancers
• Brain cancer
• Colorectal cancer
• Endometrial cancer
• Esophageal cancer
• Germ cell cancers
• Head and Neck cancer
• Liver cancer
• Lymphoma
• Mesothelioma
• Metastatic cancers¹
• Myeloma
• Neuroblastoma
• Pediatric, adolescent, and young adult cancers²
• Pediatric brain tumors
• Stomach cancer
• Sarcoma
• Thyroid cancer
• Von Hippel-Lindau syndrome malignancies³ (excluding cancers of the kidney and pancreas)

¹ 1Metastatic cancer is cancer that has spread from its original location to another place in the body, representing what are known as stage III and stage IV cancer diagnoses. While recent research has revealed that there is a genetic basis for susceptibility or resistance to metastasis, more research is needed to develop a comprehensive understanding of this complex process.

² The definition of adolescents and young adults is derived from the National Cancer Institute (https://www.cancer.gov/types/aya). Research should be targeted toward pediatric (ages 0–14 years), adolescents (ages 15–24 years), and/or young adults (ages 25–39 years).

³ Research applications in Von Hippel-Lindau syndrome must not include studies of kidney or pancreatic cancer. General studies on how VHL syndrome and malignancy are allowed.